Summary | We are studying different regulatory mechanisms and the responses of pharmaceutical companies to make orphan drugs for rare diseases available at reasonable cost |
Collaborators | Tugce Martagan (TU/e), Carla Hollak (AMC/UvA) |
Summary | We are studying different regulatory mechanisms and the responses of pharmaceutical companies to make orphan drugs for rare diseases available at reasonable cost |
Collaborators | Tugce Martagan (TU/e), Carla Hollak (AMC/UvA) |